Alcon shares fell 5% after the eye care company reported third-quarter earnings above analyst forecasts and narrowed its full-year guidance, according to Investing.com.

The company posted adjusted earnings per share of $0.91, above the analyst consensus of $0.88. Revenue reached $2.7 billion, up 5% from a year earlier and above the $2.69 billion estimate.

Alcon narrowed its full-year outlook. It now projects sales growth of about 6% on a constant currency basis, down from a previous range of 5% to 7%. It also narrowed its core diluted earnings per share growth forecast to 12% to 14%, from 12% to 15%.

David J. Endicott, Alcon's Chief Executive Officer, said the company "remain[s] on track for our 2026 objectives with year-to-date sales growth of six percent and double-digit core EPS growth, despite some specific areas of competitive pressure."

Surgical segment sales rose 4% to $1.5 billion. Implantables sales fell 2% because of competitive pressure in the U.S. IOL market, though PanOptix Pro performed strongly. Equipment sales rose 11%, supported by the Unity platform and Valeda launches. Vision Care sales increased 6% to $1.2 billion.

Core operating margin grew 1.6 percentage points to 21.8%. The report attributes the gain to $58 million in tariff refunds, manufacturing efficiencies and price increases. GAAP diluted earnings per share were $0.54, up 13%.

Alcon returned $210 million to shareholders through share repurchases in the quarter and $748 million year to date. It expanded its efficiency program, now targeting about $130 million in run-rate savings.